跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 2 天前AI 评分17

Helus Pharma Inc. 提交 6-K 文件并纳入 10 月 27 日新闻稿

6-K - Helus Pharma Inc. (0001833141) (Filer)

AI 导读

Helus Pharma Inc. 向 SEC 提交 6-K,文件注明公司前称 Cybin Inc.,并将一份日期为 10 月 27 日的新闻稿列为附件 99.1。该附件通过引用纳入公司 Form F-10 注册声明;文件由首席财务官 Greg Cavers 签署。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2026.

Commission File Number: 001-40673



Helus Pharma Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠


INCORPORATION BY REFERENCE

Exhibit 99.1 of this Form 6-K of Helus Pharma Inc. (formerly, "Cybin Inc.") (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-292294) of the Company, as amended or supplemented.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    HELUS PHARMA INC.
    (Registrant)
       
Date: October 27, 2026 By: /s/ Greg Cavers
    Name: Greg Cavers
    Title: Chief Financial Officer

EXHIBIT INDEX

99.1 News Release dated October 27, 2026

来源:SEC EDGAR · 本站存档